Department of Pharmacy Practice, Nesbitt School of Pharmacy, Wilkes University, Wilkes-Barre, PA.
Departments of Pharmacy and Medicine, Sinai Health System, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Crit Care Med. 2023 Nov 1;51(11):1502-1514. doi: 10.1097/CCM.0000000000005951. Epub 2023 Jun 7.
Iatrogenic withdrawal syndrome (IWS) associated with opioid and sedative use for medical purposes has a reported high prevalence and associated morbidity. This study aimed to determine the prevalence, utilization, and characteristics of opioid and sedative weaning and IWS policies/protocols in the adult ICU population.
International, multicenter, observational, point prevalence study.
Adult ICUs.
All patients aged 18 years and older in the ICU on the date of data collection who received parenteral opioids or sedatives in the previous 24 hours.
None.
ICUs selected 1 day for data collection between June 1 and September 30, 2021. Patient demographic data, opioid and sedative medication use, and weaning and IWS assessment data were collected for the previous 24 hours. The primary outcome was the proportion of patients weaned from opioids and sedatives using an institutional policy/protocol on the data collection day. There were 2,402 patients in 229 ICUs from 11 countries screened for opioid and sedative use; 1,506 (63%) patients received parenteral opioids, and/or sedatives in the previous 24 hours. There were 90 (39%) ICUs with a weaning policy/protocol which was used in 176 (12%) patients, and 23 (10%) ICUs with an IWS policy/protocol which was used in 9 (0.6%) patients. The weaning policy/protocol for 47 (52%) ICUs did not define when to initiate weaning, and the policy/protocol for 24 (27%) ICUs did not specify the degree of weaning. A weaning policy/protocol was used in 34% (176/521) and IWS policy/protocol in 9% (9/97) of patients admitted to an ICU with such a policy/protocol. Among 485 patients eligible for weaning policy/protocol utilization based on duration of opioid/sedative use initiation criterion within individual ICU policies/protocols 176 (36%) had it used, and among 54 patients on opioids and/or sedatives ≥ 72 hours, 9 (17%) had an IWS policy/protocol used by the data collection day.
This international observational study found that a small proportion of ICUs use policies/protocols for opioid and sedative weaning or IWS, and even when these policies/protocols are in place, they are implemented in a small percentage of patients.
与因医疗目的使用阿片类药物和镇静剂相关的医源性戒断综合征(IWS)报告发病率高,且与之相关的发病率高。本研究旨在确定成人 ICU 人群中阿片类药物和镇静剂逐渐停药以及 IWS 政策/方案的流行程度、使用情况和特征。
国际、多中心、观察性、时点患病率研究。
成人 ICU。
在数据采集日在 ICU 中年龄在 18 岁及以上、在前 24 小时内接受过静脉内阿片类药物或镇静剂的所有患者。
无。
ICU 在 2021 年 6 月 1 日至 9 月 30 日之间选择 1 天进行数据采集。收集了前 24 小时内患者的人口统计学数据、阿片类药物和镇静药物使用情况以及逐渐停药和 IWS 评估数据。主要结局是在数据采集日使用机构政策/方案对患者进行阿片类药物和镇静剂逐渐停药的比例。对来自 11 个国家的 229 个 ICU 的 2402 名患者进行了阿片类药物和镇静剂使用情况筛查;其中 1506 名(63%)患者在前 24 小时内接受了静脉内阿片类药物和/或镇静剂治疗。有 90 个(39%)ICU 制定了逐渐停药政策/方案,其中 176 名(12%)患者使用了该政策/方案,有 23 个(10%)ICU 制定了 IWS 政策/方案,其中 9 名(0.6%)患者使用了该方案。47 个(52%)ICU 的逐渐停药政策/方案未定义何时开始逐渐停药,24 个(27%)ICU 的政策/方案未指定逐渐停药的程度。有 34%(176/521)的 ICU 制定了逐渐停药政策/方案,9%(9/97)的 ICU 制定了 IWS 政策/方案在数据采集日得到使用。在根据 ICU 个体政策/方案中阿片类药物/镇静剂开始使用的持续时间确定的适合使用逐渐停药政策/方案的 485 名患者中,有 176 名(36%)使用了该政策/方案,在接受阿片类药物和/或镇静剂治疗≥72 小时的 54 名患者中,有 9 名(17%)使用了 IWS 政策/方案。
这项国际观察性研究发现,只有一小部分 ICU 使用阿片类药物和镇静剂逐渐停药或 IWS 的政策/方案,即使这些政策/方案已经存在,也只有一小部分患者会执行这些政策/方案。